Company Profiles

Psychstocks Announces its #1 DMT Play

Psychstocks believes there is only one publicly traded company that is well-positioned to capitalize on rapidly growing interest in DMT and Ayahuasca: Entheon Biomedical (CSE: ENBI), which also trades on the U.S. OTC under the symbol ENTBF.

Read more
News

BetterLife Files Patent for the Treatment of MDD Utilizing its Second-Generation Psychedelic Derivative for 2-Bromo-LSD

BetterLife Pharma (CSE: BETR) has announced this morning that it has applied for patent protection of its new 2-Bromo-LSD formulation TD-0148A and its use in the treatment of Major Depressive Disorder (MDD). BETR is beginning its pre-clinical work on TD-0148A in preparation for a Pre-IND Meeting with the FDA in March, which will allow BETR to file its IND to launch clinical trials of TD-0148A for the treatment of MDD later this year!

Read more
Alert

BETR Already Up 92.3% in 7 Trading Days!

On the afternoon of December 18th, Psychstocks announced BetterLife Pharma (CSE: BETR) at $1.17 per share as its #1 favorite Psychstock for 2021. BETR closed today at its high of day of $2.25 per share. BETR has already gained by 92.3% in only seven trading days!

Read more
Alert

Our New #1 Psychstock for 2021

Our new #1 favorite Psychstock for 2021 is Betterlife Pharma (CSE: BETR) or BETRF on the U.S. OTCQB. BETR is currently trading for $1.17 per share.

Read more
Alert

CMPS Hits Record High, RVV Breaking Out!

Psychedelics industry bellwether Compass Pathways (CMPS) gained $6.62 or 16.21% today to finish at a new all-time high closing price of $47.45 per share! We consider Revive Therapeutics (CSE: RVV) to be the #1 highest quality small-cap psychedelic biotech play.

Read more

Become a Member of Psychstocks for FREE

Holler Box